Down syndrome with and without dementia: An in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease

It is poorly understood why people with Down syndrome (DS) are at extremely high-risk of developing Alzheimer's disease (AD) compared to the general population. One explanation may be related to their extra copy of risk factors modulated by chromosome 21. Myo-inositol (mI), whose transporter gene is located on chromosome 21, has been associated with dementia in the non-DS population; however, nobody has contrasted brain mI in DS with (DS+) and without (DS-) dementia to other non-DS groups. Our primary aim was to compare the hippocampal concentration of mI ([mI]) and other brain metabolites such as N-acetylaspartate (NAA; a proxy measure of neuronal density and mitochondrial function) in DS+, DS-, and age-matched healthy controls using proton Magnetic Resonance Spectroscopy (((1))H-MRS). We compared hippocampal [mI] and other metabolites in 35 individuals with genetically-confirmed DS [DS+ (n=17, age=53±6) and DS- (n=18, age=47±8)] to age-matched healthy controls (n=13, age=51±10) adjusting for proportion of the MRS voxel occupied by cerebrospinal spinal fluid, and gray/white matter. DS+ had a significantly higher [mI] than both DS- and healthy controls. In contrast neither DS+ nor DS- differed significantly from controls in [NAA] (although NAA in DS+ was significantly lower than DS-). Our secondary aim of comparing brain metabolites in DS+ and DS- to Alzheimer's disease (AD; n=39; age=77±5) revealed that the DS+ group had significantly elevated [mI] compared to AD or DS-. [mI] may modify risk for dementia in this vulnerable population.

[1]  T. Shonk,et al.  Role of Increased Cerebral myo‐Inositol in the Dementia of Down Syndrome , 1995, Magnetic resonance in medicine.

[2]  G J Barker,et al.  Simulation of MRI cluster plots and application to neurological segmentation. , 1996, Magnetic resonance imaging.

[3]  S Lovestone,et al.  Alzheimer's disease and Down's syndrome: an in vivo MRI study , 2008, Psychological Medicine.

[4]  H. Larsson,et al.  The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium. , 1993, Magnetic resonance imaging.

[5]  S. Chantal,et al.  Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease , 2004, Brain Research.

[6]  N. Fayed,et al.  Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. , 2005, The American journal of psychiatry.

[7]  P. Renshaw,et al.  Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. , 1997, The American journal of psychiatry.

[8]  A. Wyrwicz,et al.  In vitro 1H and 31P NMR spectroscopic evidence of multiple aberrant biochemical pathways in murine trisomy 16 brain development , 2000, International Journal of Developmental Neuroscience.

[9]  M. Sabbagh,et al.  Pathological correlates of cognitive decline in Alzheimer's disease. , 2007, Panminerva medica.

[10]  G. Alexander,et al.  Relation of medial temporal lobe volumes to age and memory function in nondemented adults with Down's syndrome: implications for the prodromal phase of Alzheimer's disease. , 2002, The American journal of psychiatry.

[11]  Kuncheng Li,et al.  Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and alzheimer disease , 2009, Acta radiologica.

[12]  W. Müller,et al.  Altered Ca2+ Signaling and Mitochondrial Deficiencies in Hippocampal Neurons of Trisomy 16 Mice: A Model of Down’s Syndrome , 1998, The Journal of Neuroscience.

[13]  B. Tycko,et al.  Earlier onset of Alzheimer's disease in men with Down syndrome , 1998, Neurology.

[14]  D. Westaway,et al.  Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model , 2006, Nature Medicine.

[15]  Marinette van der Graaf,et al.  In vivo magnetic resonance spectroscopy: basic methodology and clinical applications , 2009, European Biophysics Journal.

[16]  P. Fraser,et al.  Inositol Stereoisomers Stabilize an Oligomeric Aggregate of Alzheimer Amyloid β Peptide and Inhibit Aβ-induced Toxicity* , 2000, The Journal of Biological Chemistry.

[17]  N. Spinner,et al.  The human osmoregulatory Na+/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21. , 1995, Genomics.

[18]  H Rusinek,et al.  The hippocampus in aging and Alzheimer's disease. , 1995, Neuroimaging clinics of North America.

[19]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[20]  G. Alexander,et al.  High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study. , 1999, The American journal of psychiatry.

[21]  A. Simmons,et al.  Hippocampal myo-inositol and cognitive ability in adults with Down syndrome: an in vivo proton magnetic resonance spectroscopy study. , 2005, Archives of general psychiatry.

[22]  E. Jazin,et al.  Alzheimer's disease: mRNA expression profiles of multiple patients show alterations of genes involved with calcium signaling , 2006, Neurobiology of Disease.

[23]  A. Taanila,et al.  Mental health, behaviour and intellectual abilities of people with Down syndrome. , 2006, Down's syndrome, research and practice : the journal of the Sarah Duffen Centre.

[24]  Patrizia Mecocci,et al.  Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy , 2006, Neurobiology of Aging.

[25]  T. Murata,et al.  In vivo proton magnetic resonance spectroscopy study on premature aging in adult Down's syndrome , 1993, Biological Psychiatry.

[26]  H. Wiśniewski,et al.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome , 1985, Annals of neurology.

[27]  V. Prasher,et al.  Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population , 2004, International journal of geriatric psychiatry.

[28]  F. Huppert,et al.  Neuropsychological assessment of older adults with Down's syndrome: an epidemiological study using the Cambridge Cognitive Examination (CAMCOG). , 1999, The British journal of clinical psychology.

[29]  P. Eikelenboom,et al.  Dementia and mortality in persons with Down's syndrome. , 2006, Journal of intellectual disability research : JIDR.

[30]  G D Pearlson,et al.  MRI brain changes in subjects with Down syndrome with and without dementia , 1998, Developmental medicine and child neurology.

[31]  G D Pearlson,et al.  MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia. , 1999, The American journal of psychiatry.

[32]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[33]  D. Auer,et al.  Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease , 2005, Neuroscience Letters.

[34]  E Moore,et al.  Serial precision of metabolite peak area ratios and water referenced metabolite peak areas in proton MR spectroscopy of the human brain. , 1998, Magnetic resonance imaging.

[35]  J. McLaurin,et al.  Properties of scyllo–inositol as a therapeutic treatment of AD-like pathology , 2007, Journal of Molecular Medicine.

[36]  M. Miyamoto,et al.  Effect of TAK-147, a novel AChE inhibitor, on cerebral energy metabolism , 1996, Neurobiology of Aging.

[37]  J. McLaurin,et al.  Modulation of amyloid‐β aggregation and toxicity by inosose stereoisomers , 2008, The FEBS journal.

[38]  P. Fraser,et al.  Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. , 2000, The Journal of biological chemistry.

[39]  P. Fraser,et al.  Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. , 1998, Journal of molecular biology.